Click to view our statement on Accessibility
Back
Foley Viewpoints

The Foreign Corrupt Practices Act: Risk-Management and Compliance Strategies For Life Sciences and Pharmaceutical Companies

16 October 2009

Author(s)

Gregory Husisian

Partner

Washington, D.C. 202.945.6149

Related Insights

View All Posts
20 December 2024 Health Care Law Today

GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024 Manufacturing Industry Advisor

Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment

The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024 Health Care Law Today

HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape

The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.